LTBP-1 CRISPR/Cas9 KO Plasmid (h): sc-402289
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LTBP-1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LTBP-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LTBP-1 Antibody (H-1): sc-271140
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LTBP-1 CRISPR/Cas9 KO Plasmid (h) | sc-402289 | 20 µg | $397.00 |
Overview
LTBP1 encodes latent transforming growth factor beta binding protein 1 (LTBP-1), an extracellular matrix glycoprotein that binds the latent TGF-β complex and regulates its sequestration, activation, and spatial presentation to cells. By controlling TGF-β bioavailability, LTBP-1 influences SMAD-dependent signaling and downstream programs in matrix remodeling, epithelial–mesenchymal transition, cell adhesion, and tissue homeostasis. LTBP1 function is closely linked to fibrillin microfibril organization and mechanoregulated TGF-β activation, connecting extracellular matrix architecture with cytokine signaling. Dysregulated LTBP1/TGF-β axis activity is implicated in fibrosis-associated remodeling, cancer-associated stromal signaling, and vascular/connective tissue pathobiology, making it relevant for mechanistic studies of microenvironment-driven phenotypes.
LTBP-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the LTBP1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the LTBP1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the LTBP1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LTBP-1 protein expression.
This CRISPR knockout system enables efficient generation of LTBP1-deficient cell models for investigation of LTBP-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting LTBP1 exon(s) critical for LTBP-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple LTBP1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LTBP-1 CRISPR/Cas9 KO Plasmid (h) and LTBP-1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the LTBP1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LTBP-1 HDR Plasmid (h) and LTBP-1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by LTBP1 homology arms to support homology-directed repair at defined LTBP1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.